EPLG news
  • We congratulate AIT Therapeutics Inc. (AIT), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, for recently raising over $9 million in a private placement.

    AIT initially came to Elmore Patent Law Group to analyze it’s intellectual property and develop a comprehensive strategy to identify and protect its key elements. We are pleased to have supported AIT during this placement and look forward to continuing to counsel AIT as they work to bring their products to market.